ATE304009T1 - Neue benzotriazole mit entzündungshemmender wirkung - Google Patents

Neue benzotriazole mit entzündungshemmender wirkung

Info

Publication number
ATE304009T1
ATE304009T1 AT02252153T AT02252153T ATE304009T1 AT E304009 T1 ATE304009 T1 AT E304009T1 AT 02252153 T AT02252153 T AT 02252153T AT 02252153 T AT02252153 T AT 02252153T AT E304009 T1 ATE304009 T1 AT E304009T1
Authority
AT
Austria
Prior art keywords
inhibitor
new
definitions
heterocyclyl
cycloalkyl
Prior art date
Application number
AT02252153T
Other languages
English (en)
Inventor
Mark Anthony Dombroski
Ellen Ruth Laird
Michael Anthony Letavic
Kim Francis Mcclure
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE304009T1 publication Critical patent/ATE304009T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02252153T 2001-04-04 2002-03-26 Neue benzotriazole mit entzündungshemmender wirkung ATE304009T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28133101P 2001-04-04 2001-04-04

Publications (1)

Publication Number Publication Date
ATE304009T1 true ATE304009T1 (de) 2005-09-15

Family

ID=23076827

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02252153T ATE304009T1 (de) 2001-04-04 2002-03-26 Neue benzotriazole mit entzündungshemmender wirkung

Country Status (9)

Country Link
US (1) US6664395B2 (de)
EP (1) EP1247810B1 (de)
JP (1) JP3832646B2 (de)
AT (1) ATE304009T1 (de)
BR (1) BR0201087A (de)
CA (1) CA2379903C (de)
DE (1) DE60205974T2 (de)
ES (1) ES2247271T3 (de)
MX (1) MXPA02003454A (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
JP2004525109A (ja) 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
EP2048142A3 (de) * 2001-04-26 2009-04-22 Eisai R&D Management Co., Ltd. Stickstoffhaltige, kondensierte zyklische Verbindung mit Pyrazolyl-Gruppe als substituierende Gruppe und pharmazeutische Zusammensetzung daraus
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US7037923B2 (en) 2002-08-30 2006-05-02 Pfizer, Inc. Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
PA8579601A1 (es) 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
US7012143B2 (en) 2002-08-30 2006-03-14 Dombroski Mark A Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US6949652B2 (en) 2002-08-30 2005-09-27 Pfizer, Inc. Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
US7005523B2 (en) 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
US20060122240A1 (en) * 2002-11-05 2006-06-08 Arena Pharmaceuticals, Inc. Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
EP1601672B1 (de) 2003-02-14 2006-07-26 Pfizer Products Inc. Triazolopyridine als entzündungshemmende verbindungen
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
WO2004099127A1 (en) * 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
CA2526285A1 (en) 2003-05-15 2004-12-23 Arqule, Inc. Inhibitors of p38 and methods of using the same
AU2004305318A1 (en) * 2003-12-18 2005-07-07 Pfizer Products Inc. Methods of treating acute inflammation in animals with p38 MAP kinase inhibitors
WO2006010082A1 (en) * 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
CA2584368A1 (en) * 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
PE20070404A1 (es) * 2005-07-29 2007-05-10 Wyeth Corp Compuestos derivados de cianopirrol-sulfonamida como moduladores del receptor de progesterona
PE20070182A1 (es) * 2005-07-29 2007-03-06 Wyeth Corp Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
PE20070341A1 (es) * 2005-07-29 2007-04-13 Wyeth Corp Derivados de pirrol como moduladores del receptor de progesterona
AR070986A1 (es) 2008-04-04 2010-05-19 Lilly Co Eli Compuesto de 3-indazoil-4 -piridilisotiazoles, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para tratar la ansiedad
WO2009155389A1 (en) * 2008-06-20 2009-12-23 Bristol-Myers Squibb Company Triazolopyridine compounds useful as kinase inhibitors
CA2744713A1 (en) * 2008-12-05 2010-06-10 Arqule, Inc. Raf inhibitors and their uses
WO2010141360A1 (en) * 2009-06-05 2010-12-09 Merck Sharp & Dohme Corp. Biaryl benzotriazole derivatives
US20160194336A1 (en) * 2012-12-17 2016-07-07 Allinky Biopharma P38 mapk inhibitors for the treatment of inflammatory diseases
WO2014208296A1 (ja) * 2013-06-25 2014-12-31 イハラケミカル工業株式会社 ニトロベンゼン化合物を製造する方法
CN105481863B (zh) * 2015-12-09 2018-11-02 科贝源(北京)生物医药科技有限公司 2-甲基-6-(4-甲基苯磺酰基)-1,4,5,6-四氢咪唑并[4,5-d][1]苯并氮杂*的合成方法
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
CN110831593A (zh) * 2017-06-14 2020-02-21 特维娜有限公司 用于调节s1p1活性的化合物及其使用方法
ES2927715T3 (es) 2017-10-05 2022-11-10 Fulcrum Therapeutics Inc Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD
US20220380317A1 (en) * 2019-06-27 2022-12-01 Nanyang Technological University Compounds having antimalarial activity
MX2022005766A (es) 2019-11-19 2022-08-08 Trevena Inc Compuestos y métodos para la preparación de compuestos moduladores de esfingosina 1-fosfato tipo 1 (s1p1).
CN115490646A (zh) * 2022-10-10 2022-12-20 安徽昊帆生物有限公司 3-硝基-1，2，4-三氮唑的制备方法
TWI911045B (zh) * 2025-02-08 2026-01-01 碁達科技股份有限公司 防硫化膠及具有金屬的製品

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5283753A (en) * 1976-01-01 1977-07-12 Fuji Photo Film Co Ltd Benzotriazole
US5716972A (en) 1993-01-13 1998-02-10 Smithkline Beecham Corporation Pyridyl substituted imidazoles
US5871934A (en) 1993-09-17 1999-02-16 Smithkline Beecham Corporation Screening methods using cytokine suppressive anti-inflammatory drug (CSAID) binding proteins
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US5756499A (en) * 1996-01-11 1998-05-26 Smithkline Beecham Corporation Substituted imidazole compounds
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
CA2333157A1 (en) 1998-05-26 1999-12-02 Smithkline Beecham Corporation Novel substituted imidazole compounds
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
US6350744B1 (en) 1998-11-20 2002-02-26 Merck & Co., Inc. Compounds having cytokine inhibitory activity
EP1140916B1 (de) 1998-12-16 2002-11-13 Aventis Pharma Limited Heteroaryl-zyklische acetale
EP1140083A4 (de) 1999-01-08 2004-01-02 Smithkline Beecham Corp Neue verbindungen
EP2298311B1 (de) 1999-01-13 2012-05-09 Bayer HealthCare LLC Omega-carboxyarylsubstituierte-Diphenyl-Harnstoffe als p38-Kinasehemmer
CO5170501A1 (es) 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO

Also Published As

Publication number Publication date
DE60205974D1 (de) 2005-10-13
EP1247810B1 (de) 2005-09-07
US20030078432A1 (en) 2003-04-24
CA2379903A1 (en) 2002-10-04
JP3832646B2 (ja) 2006-10-11
CA2379903C (en) 2006-08-01
EP1247810A1 (de) 2002-10-09
DE60205974T2 (de) 2006-06-29
US6664395B2 (en) 2003-12-16
ES2247271T3 (es) 2006-03-01
MXPA02003454A (es) 2004-07-16
BR0201087A (pt) 2003-05-27
JP2002308872A (ja) 2002-10-23

Similar Documents

Publication Publication Date Title
DE60205974D1 (de) Neue Benzotriazole mit entzündungshemmender Wirkung
DE69912823D1 (de) Benzamid-derivate und ihre verwendung als cytokine inhibitoren
WO2020140005A3 (en) 1 h-pyrrolo[2,3-b]pyridine derivatives and related compounds as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
NZ509318A (en) Amide derivatives, their preparation and use in the treatment of diseases mediated by cytokines
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
DE602004024988D1 (de) 2-aminopyrimidin-derivate als raf-kinase-hemmer
ATE466581T1 (de) Verbindungen auf pyrimidin-basis als gsk-3-hemmer
NO20040511L (no) Aminoisoxazolderivater som kinaseinhibitorer
ITMI20010562A1 (it) Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
ATE221047T1 (de) Amid-derivate, die als inhibitoren von zytokininen nützlich sind
DK0529568T3 (da) Nye oralt aktive elastaseinhibitorer
NL980001I1 (nl) Therapeutische heterocyclische verbindingen.
NO995006L (no) Nye forbindelser
DK1438053T3 (da) Pyrimidinderivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
TR200200234T2 (tr) Tirozin Protein kinaz SYK purin türevleri inhibitörleri
NL300175I2 (nl) Methylsulfonylfenyl-2-(5H)-furanonen als remmers van COX-2.
NO20021448D0 (no) Nye tiazolo (4,5-D)-pyrimidinforbindelser
ATE195128T1 (de) Steroidnitrit/nitratesterderivate und ihre verwendung als entzündungshemmende medikamente
BRPI0410653A (pt) composto, composição farmacêutica, e, uso de um composto ou um sal, solvato, hidrato ou n-óxido farmaceuticamente aceitável do mesmo
DK0585155T3 (da) Trifluormethylketon-peptidderivater med HLE-inhiberende aktivitet, deres fremstilling og farmaceutiske præparater
ES2138983T3 (es) Uso de derivados del acido 2-(n-(2-aminoetil)amino)-acetico para el tratamiento de enfermedades condicionadas por glicosilacion no enzimatica.
SE8801729D0 (sv) Purine derivatives for use in therapy
MXPA03010269A (es) Derivados de 2,5-disubstituida piridina, pirimidina, piridazina y 1,2,4-triazina para usarse como inhibidores de p38.
ATE359791T1 (de) Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties